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Abstract 1 
The genetic basis of hypoplastic left heart syndrome (HLHS) remains unknown, and the lack of 2 
animal models to reconstitute the cardiac maldevelopment has hampered the study of this 3 
disease. This study investigated the altered control of transcriptional and epigenetic programs 4 
that may affect the development of HLHS by using disease-specific induced pluripotent stem 5 
(iPS) cells. Cardiac progenitor cells (CPCs) were isolated from patients with congenital heart 6 
diseases to generate patient-specific iPS cells. Comparative gene expression analysis of HLHS- 7 
and biventricle (BV) heart-derived iPS cells was performed to dissect the complex genetic 8 
circuits that may promote the disease phenotype. Both HLHS- and BV heart-derived CPCs were 9 
reprogrammed to generate disease-specific iPS cells, which showed characteristic human 10 
embryonic stem cell signatures, expressed pluripotency markers, and could give rise to 11 
cardiomyocytes. However, HLHS-iPS cells exhibited lower cardiomyogenic differentiation 12 
potential than BV-iPS cells. Quantitative gene expression analysis demonstrated that 13 
HLHS-derived iPS cells showed transcriptional repression of NKX2-5, reduced levels of TBX2 14 
and NOTCH/HEY signaling, and inhibited HAND1/2 transcripts compared with control cells. 15 
Although both HLHS-derived CPCs and iPS cells showed reduced SRE and TNNT2 16 
transcriptional activation compared with BV-derived cells, co-transfection of NKX2-5, HAND1, 17 
and NOTCH1 into HLHS-derived cells resulted in synergistic restoration of these promoters 18 
activation. Notably, gain- and loss-of-function studies revealed that NKX2-5 had a predominant 19 
impact on NPPA transcriptional activation. Moreover, differentiated HLHS-derived iPS cells 20 
showed reduced H3K4 dimethylation as well as histone H3 acetylation but increased H3K27 21 
trimethylation to inhibit transcriptional activation on the NKX2-5 promoter. These findings 22 
suggest that patient-specific iPS cells may provide molecular insights into complex 23 
transcriptional and epigenetic mechanisms, at least in part, through combinatorial expression of 24 
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NKX2-5, HAND1, and NOTCH1 that coordinately contribute to cardiac malformations in 1 
HLHS. 2 
4 
 
Introduction 1 
Single ventricle (SV) physiology including hypoplastic left heart syndrome (HLHS) is 2 
characterized by obstruction of the left ventricle (LV) in association with absence or 3 
underdevelopment of the left ventricular chamber morphogenesis that is not capable of 4 
supporting systemic cardiac output. Infants with SV physiology theoretically undergo two major 5 
medical treatments: cardiac transplantation and three-stage palliative reconstruction [1,2]. 6 
However, their long-term survival has been shown to be remarkably lower than that of patients 7 
with all other congenital heart diseases [3].  8 
Embryonic development in the heart is controlled by a core set of essential cardiac 9 
transcription factors that regulate progenitor cell migration and expansion, morphogenesis of 10 
cardiac chambers, and maturation of structural proteins. Genetically, HLHS has been associated 11 
with chromosome anomalies, but no single genetic basis has been found to be specifically 12 
linked to this syndrome [4]. Although the majority of cases are sporadic, rare patients who 13 
inherited multiple gene variants suggest that HLHS may be pathophysiologically heterogeneous 14 
and caused by cumulative effects that are poorly understood [5].  15 
Obviously, most of the disease-causing genes for HLHS remain to be identified; however, 16 
the rarity of kindred with familial recurrences of HLHS with viable penetrance and phenotype 17 
has made linkage studies difficult. Patient-derived cardiac progenitor cells (CPCs) may allow 18 
researchers to investigate early cardiac development programs that have already acquired the 19 
disease phenotypes. A simultaneous tractable system, reported here, may facilitate the 20 
identification of crucial determinants in HLHS by modeling the disease with reprogramming 21 
technology that enables comprehensive analysis of patient-specific genetic disorders prior to 22 
disease onset. 23 
iPS cells, which closely resemble embryonic stem (ES) cells, can be derived from human 24 
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somatic tissues from a variety of diseases to recapitulate complex physiological phenotypes. 1 
Patient-specific iPS cells may provide an additional tool for studying human heart disease [6]. 2 
Here, to identify the key elements responsible for hypoplasia of left heart development, we 3 
generated disease-specific iPS cells in patients with congenital heart malformation, identified 4 
unique genes differentially expressed in HLHS, and explored the responsible regulatory network 5 
involved in myocardial patterning and morphogenesis during cardiac development with respect 6 
to LV hypoplasia in humans.  7 
8 
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Materials and Methods 1 
Ethics Statement 2 
Written informed consent was obtained from the parents of the patients before the collection of 3 
tissue samples. The study protocols using human tissue samples and animals were approved by 4 
the Research Ethics Committee of Okayama University. As control RNA of human embryonic 5 
stem cells, khESC-1-derived RNA was isolated and provided by Keio University as previously 6 
reported [7]. 7 
 8 
Tissue Sample and Cell Culture 9 
Myocardial tissues were obtained from right atria during open-heart surgery shortly after 10 
cardiopulmonary bypass. Cardiac specimens were digested using 0.4% type II collagenase and 11 
0.01% DNAse and minced to produce a single-cell suspension. The cells were seeded at 20 12 
cells/l in ultra-low culture dishes to generate cardiospheres with growth medium containing 13 
DMEM/F12 (Invitrogen), 10% fetal bovine serum, 20 ng/ml recombinant human epidermal 14 
growth factor (EGF; Wako), 40 ng/ml recombinant human basic fibroblast growth factor (bFGF; 15 
Wako), 50 U/ml penicillin, and 50 mg/ml streptomycin as previously described [8,9]. 16 
Cardiospheres were mechanically harvested, digested, and cultured on poly-D-lysine-coated 17 
dishes to obtain CPCs.  18 
 19 
Generation and Differentiation of Patient-Specific iPS Cells 20 
For iPS cell generation, CPCs were infected with concentrated retroviruses pseudotyped with 21 
vesicular stomatitis virus surface protein (VSV-G; Cell Biolabs, Inc.) encoding the human 22 
transcription factors OCT4, KLF4, SOX2, and MYC (Addgene) as previously described [10]. 23 
Transfected CPCs were maintained on mouse SNL feeders for 7 days post-infection and then 24 
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cultured in DMEM/F12 containing 20% Knockout Serum Replacement, 2 mM L-glutamine, 0.1 1 
mM nonessential amino acid (NEAA), 0.1 mM 2-mercaptoethanol (2-ME), 50 U/mL penicillin, 2 
50 mg/ml streptomycin (all from Invitrogen), and 4 ng/mL recombinant human bFGF until iPS 3 
colonies appeared. Control human iPS cells (201B7; HPS0063) were purchased from RIKEN 4 
Bioresource Center.  5 
Cardiac differentiation was induced on Matrigel-coated culture dishes in feeder-free 6 
conditions. The medium was replaced with serum-free medium (RPMI1640, Invitrogen) 7 
containing B27 (RPMI/B27, Invitrogen) and supplemented with 100 ng/ml human recombinant 8 
activin A for 24 h, followed by incubation with 10 ng/ml human recombinant bone 9 
morphogenetic protein (BMP) 4 for an additional 4 days (all from R&D Systems). 10 
 11 
Immunofluorescence 12 
Cells were fixed in 4% paraformaldehyde for 30 min and stained in blocking buffer with 13 
primary antibodies against NANOG (R&D Systems), SSEA-3 (BD Biosciences), OCT4, 14 
SSEA-4, TRA-1-60, and TRA-1-81 (all from Millipore), followed by incubation with Alexa 15 
Fluor 488/546/594 secondary antibodies (Molecular Probes). To evaluate cardiomyocyte 16 
differentiation, fixed cells were permeabilized with 0.2% Triton X-100 for 30 min and incubated 17 
with primary antibodies directed against cardiac troponin-T (Abcam). Cells were counterstained 18 
with DAPI (Molecular Probes) and visualized using a confocal laser scanning microscope 19 
(FV-1000, Olympus, Tokyo). Alkaline phosphatase staining was performed using Alkaline 20 
Phosphatase Detection kit (Millipore) according to the manufacturer’s instructions. 21 
 22 
Bisulfite Sequencing and Karyotype Analysis 23 
Genomic DNA (1 g) was extracted (QIAGEN) from patient-derived undifferentiated CPCs or 24 
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iPS cells and processed for bisulfite conversion by using a Methylamp DNA modification kit 1 
(Epigentek). The promoter regions of OCT4 and NANOG were then amplified by PCR using 2 
primers as previously described (Table S2) [11]. The PCR products were subcloned into 3 
pCRII-TOPO vector (Invitrogen) and analyzed using ABI 3700 DNA analyzer (Applied 4 
Biosystems). Chromosomal analysis was performed using the standard G-banding chromosome 5 
detection method (SRL). 6 
 7 
Teratoma Formation 8 
Disease-specific iPS cells (0.6-1x10
6
 cells) were directly injected into the testes of NOD/SCID 9 
mice. At 10 to 12 weeks after transplantation, teratomas were dissected and processed for 10 
paraffin embedding and hematoxylin and eosin staining.  11 
 12 
Real-Time RT-PCR and Global Gene Expression Analysis 13 
Total RNA was isolated using TRIzol reagent (Invtrogen) and cDNA was synthesized using 14 
Reverse Transcription Kit (QIAGEN). Quantitative RT-PCR was performed using FastStart 15 
Universal Probe Master (Roche) analyzed with the 7300 real-time PCR system (Applied 16 
Biosystems) and primers. All experiments were conducted more than five times with three 17 
different clonal derivatives. PCR was carried out using Ex Taq (Takara). All data were 18 
normalized using 2-microglobulin (B2M) and human heart tissue for comparisons. Primer 19 
sequences are shown in Table S2. To assess the transcriptional profile, cyanine-labeled antisense 20 
RNA was amplified and hybridized with a Whole Human Genome Microarray (Agilent). Data 21 
were analyzed using GeneSpring GX10.0 software and gene expression levels were normalized 22 
using Robust Multi-array Average algorithm.  23 
 24 
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ChIP Assay 1 
The experiments of chromatin immunoprecipitation (ChIP) were performed using ChIP-IT 2 
Express Enzymatic Magnetic Chromatin Immunoprecipitation kit (Active Motif). Briefly, 1x10
6
 3 
CPCs, undifferentiated iPS cells, and differentiated iPS cells were cross-linked with 1% 4 
formaldehyde solution for 5 min at room temperature. The cells were harvested and nuclei were 5 
extracted, lysed, and enzymatically sheared to obtain chromatin. Immunoprecipitation was 6 
performed on an end-to-end rotation overnight at 4
°
C using the following antibodies: IgG 7 
(Upstate, Millipore 12-370), H3K4me2 (Upstate, Millipore 07-030), H3K27me3 (Upstate, 8 
Millipore 07-449), and acH3 (Upstate, Millipore 06-599). Crosslinking between DNA and 9 
proteins was reversed. DNA was purified after proteinase K digestion using Chromatin IP DNA 10 
Purification Kit (Active Motif). All precipitated DNA samples were amplified and quantitated 11 
by real-time PCR with SYBR Premix Ex Taq II (TaKaRa) and NKX2-5 ChIP primers (Table 12 
S2). Signals corresponding to each antibody were normalized by respective input. 13 
 14 
Promoter Assays 15 
The TNNT2 (HPRM12846-PG04) and NPPA (natriuretic peptide A; HPRM23486-PG04) 16 
promoter activities were measured using a Dual Luminescence Assay Kit with a dual reporter 17 
construct containing Gaussia luciferase (GLuc) and secreted alkaline phosphatase (SEAP) side 18 
by side from a single sample (all from GeneCopoeia, Inc.). Each promoter is placed upstream of 19 
the GLuc reporter gene and contains a specific cardiac transcription factor as an insert. A 20 
secondary reporter gene SEAP was used to monitor the transfection efficiency for normalization. 21 
To detect serum response element (SRE) promoter activities, both SRE fragment (pGL4.33 22 
[luc2P/SRE/Hygro], Promega) and pGL4.74 (hRluc/TK, Promega) were co-transfected into 23 
human cells by using X-tremeGene HP reagent (Roche). The relative expression of SRE (luc2P) 24 
10 
 
construct was normalized using a control vector (hRluc) introduced into the same cells. Human 1 
cells were transfected with human NKX2-5 cDNA (SC122678), human NKX2-5 shRNA (short 2 
hairpin RNA; TR311165B), human HAND1 cDNA (SC122690), human HAND1 shRNA 3 
(TR316857C), human NOTCH1 cDNA (SC308883), or human NOTCH1 shRNA (TR302916D) 4 
along with single- or dual-reporter constructs (all from OriGene Technologies, Inc.). The 5 
luciferase activities were measured by the Glomax-Multi+Detection System (Promega) 48 hours 6 
after transfection. 7 
 8 
Statistics 9 
Results are presented as the mean±S.D. The significance of differences was evaluated by paired 10 
or unpaired Student’s t test. A p value of less than 0.05 was considered significant. 11 
12 
11 
 
Results 1 
Generation of Disease-Specific iPS Cells Using Patient-Derived CPCs 2 
CPCs were isolated from the right atria of patients with congenital heart diseases undergoing 3 
cardiac surgery (Figure 1A). Individual cardiosphere-derived CPCs were isolated and infected 4 
with a combination of retroviruses encoding the transcription factors OCT4, KLF4, SOX2, and 5 
MYC as previously reported (Figure 1B) [11]. Among the iPS clones generated, five HLHS-iPS 6 
clones (iPS30, iPS46, iPS59, iPS68, and iPS72) and one BV-iPS clone (iPS65), obtained from a 7 
total anomalous pulmonary venous connection (TAPVC) patient, could propagate robustly when 8 
maintained on SNL feeder cells. We then used the iPS clones (iPS30-, iPS46-, and 9 
iPS72-HLHS) and the iPS65 clone (iPS-BV) for further evaluation in this study. Genomic 10 
integration of viral transgene was confirmed by RT-PCR. The reactivation of endogenous genes 11 
OCT4 and NANOG led to higher levels in patient-specific iPS cells than in parental CPCs 12 
(Figure 1C). We also examined the expression of viral transgenes; RT-PCR showed that four 13 
factors (transgenes) were efficiently silenced in the established iPS cell lines; they were 14 
maintained for more than 15 passages and examined at 3 months post-infection (Figure 1D). 15 
 16 
Characterization of Patient-Derived iPS Cells 17 
The two types of disease-specific iPS cell grew at similar rates and uniformly expressed 18 
stringent pluripotent markers such as OCT4, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and 19 
NANOG, as determined by immunofluorescence (Figures 2A and B). We next sought to confirm 20 
the epigenetic reprogramming in individual iPS cells. Bisulfite sequencing analysis was 21 
performed to verify the degree of DNA methylation of the OCT4 and NANOG promoters 22 
(Figures 2C and D). CpG dinucleotides in both promoter regions were highly demethylated in 23 
both patient-derived iPS cells relative to parental CPCs. Consistent with their ES-like 24 
12 
 
morphology, both HLHS- and BV-derived iPS cells were positive for alkaline phosphatase 1 
staining (Figure 3A) and could maintain a normal karyotype for at least 10 weeks (Figure 3B).  2 
 3 
Molecular Signatures of Patient-Derived CPCs and iPS Cells 4 
We next performed global gene expression analysis on patient-specific iPS cells and parental 5 
CPCs using oligonucleotide microarray (Figure 3C). The heat map image showed that the 6 
expression profiles of both iPS cells were similar to those in control human iPS cells (clone 7 
201B7) and human embryonic stem cells (clone khESC-1), but different from that in parental 8 
CPCs. Consistent with this, hierarchical clustering analysis demonstrated that disease-specific 9 
iPS cells closely resembled control human iPS cells, but were distinct from parental CPCs. Of 10 
particular note, pluripotency-associated genes represented by NANOG, POU5F1 (OCT4), and 11 
TDGF1 were expressed at remarkable levels in iPS cells compared with the levels in parental 12 
CPCs analyzed using three-independent CPC lines (Table S1). Patient-derived CPCs 13 
significantly expressed typical gene transcripts indispensable for progenitor cell proliferation 14 
and differentiation, including IL1B, GREM1, LIF, TGFBR2, and IFGBP7 [12-15] , and also 15 
showed a vascular-lineage-committed phenotype by expressing EDN1, LMO2, and VEGFC 16 
(Table S1).  17 
To assess the in vivo pluripotency, iPS cells generated from patients were injected into 18 
NOD/SCID mice. Ten to twelve weeks after transplantation, both iPS cells gave rise to 19 
teratomas originating from all three embryonic layers, including gut-like epithelia (endoderm), 20 
cartilage and adipose tissue (mesoderm), and neuroectodermal tissue (ectoderm) (Figure 4). 21 
 22 
Cardiomyocyte Differentiation Potential of Disease-Specific iPS Cells 23 
Upon cardiac differentiation, both HLHS- and BV-derived iPS cells generated cells that 24 
13 
 
expressed typical cardiac structural proteins, cardiac troponin-T (TNNT2) verified by 1 
immunostaining, suggesting that HLHS-derived iPS cells are capable of generating 2 
cardiomyocytes in vitro (Figure 5A). Quantitative RT-PCR revealed that TNNT2 expression was 3 
significantly upregulated at 3 weeks after differentiation compared with that at baseline in both 4 
types of iPS-derived cardiomyocyte; however, HLHS-derived iPS cells showed reduced 5 
cardiomyogenic potential than those from control and BV heart (Fig. 5B).  6 
 7 
Reduced Transcriptional Regulatory Programs During Cardiac Differentiation in HLHS-Derived 8 
iPS Cells 9 
To determine whether HLHS-derived iPS cells have a distinct cardiac differentiation program, 10 
quantitative RT-PCR was performed. We found that cardiac transcriptional factors such as 11 
NKX2-5 and HAND1, known to drive cardiac growth and morphogenesis through primary heart 12 
field development, were significantly downregulated in HLHS-derived iPS cells at 2 to 3 weeks 13 
after differentiation compared with their levels in control 201B7 iPS- and BV-iPS-derived 14 
cardiomyocytes (Fig. 6) [16]. HAND2 gene expression, which is known to preferentially control 15 
right heart morphogenesis but has a partially cumulative role with HAND1 in ventricular 16 
chamber formation, was also suppressed [17]. T-box transcription factor TBX2, a particularly 17 
important regulator for outflow tract cushion development and atrioventricular canal formation 18 
as myocardial patterning, was significantly reduced in differentiated HLHS-derived iPS cells 19 
[18]. In addition, reduced expression of NOTCH/HEY signaling was found. The decreased 20 
transcripts of these genes may be associated with obstruction in the inflow and outflow tracts 21 
seen in patients with HLHS due to the developmental defects in the regions of atrioventricular 22 
and outflow tract myocardium [19]. These data suggest that HLHS-derived iPS cells have the 23 
ability to give rise to cardiomyocytes; however, these cells had suppressed levels of 24 
14 
 
indispensable genes involved in progenitor cell expansion and differentiation to initiate 1 
cardiogenesis, atrioventricular canal formation, and left ventricular outflow tract development to 2 
achieve functional ventricular growth. 3 
 4 
NKX2-5, HAND1, and NOTCH1 Are Indispensable to Restore the Activation of 5 
Cardiac-Specific Promoters in HLHS-Derived Cells 6 
Next, we sought to determine whether NKX2-5, HAND1, and NOTCH1 genes might be involved 7 
in the control of cardiac-specific promoter activities during the development of HLHS. Three 8 
possible targets of cardiac-related promoters, namely, SRE, TNNT2, and NPPA, were examined. 9 
To demonstrate that the generated shRNAs were specific for NKX2-5, HAND1, and NOTCH1, 10 
we performed transient transfection experiments to verify the inhibitory effects of respective 11 
gene expressions (Figure S1A). Four sets of shRNA for each gene were generated and 12 
transfected into HLHS-derived CPCs with either the full-length cDNA of interest or combined 13 
corresponding shRNA and cultured for 48 hours. Real-time RT-PCR analyses were performed to 14 
determine the appropriate ones for subsequent experiments. The inhibitory effects of selected 15 
shRNAs were confirmed by using additional clones of HLHS- and BV-derived CPCs (Figure 16 
S1B). 17 
To investigate whether NKX2-5, HAND1, and NOTCH1 might be the crucial transcriptional 18 
activators during cardiomyocyte differentiation, we performed co-transfection studies using the 19 
luciferase reporters driven by SRE, TNNT2, and NPPA promoters, respectively. As shown in 20 
Figures 7A and B, both HLHS-derived CPCs and iPS cells demonstrated a significant decrease 21 
in SRE transcriptional activation that was synergistically increased when NKX2-5, HAND1, 22 
and NOTCH1 were co-transfected into the cells, which was equivalent to the level in 23 
BV-derived cells without exogenous gene induction. To address whether these transcriptional 24 
15 
 
factors are capable of suppressing endogenous SRE activation, we transfected shRNAs into 1 
BV-derived CPCs and found that either single shRNA or combinatorial treatment had the 2 
potential to suppress SRE promoter activities (Figure 7G). We therefore hypothesized that these 3 
transcriptional factors may also participate in cardiomyocyte maturation. A TNNT2 4 
promoter-driven luciferase reporter was used in patient-derived CPCs and iPS cells with or 5 
without exogenous gene transfection. We found that BV-derived CPCs and iPS cells showed 6 
prominent TNNT2 promoter activity compared with those in two independent HLHS-derived 7 
cells (Figures 7C and D). Induction of NKX2-5, HAND1, and NOTCH1 synergistically restored 8 
the reduced TNNT2 transcriptional activation in both HLHS-derived CPCs and iPS cells. 9 
Loss-of-function studies using shRNAs showed that combinatorial inhibition of three genes, 10 
except for shHAND1 alone, could markedly suppress the TNNT2 promoter activities (Figure 11 
7H). NPPA promoter-driven luciferase assays demonstrated a striking finding that either 12 
NKX2-5 alone or combinatorial gene transfection containing NKX2-5 could fully restore the 13 
NPPA transcriptional activation in both HLHS-derived cell types (Figures 7E and F). This great 14 
impact of NKX2-5 on the NPPA promoter was confirmed by shRNA experiments that 15 
demonstrated that inhibition of NKX2-5 alone resulted in significant reduction of NPPA 16 
transcriptional activation in BV-derived CPCs (Figure 7I). 17 
 18 
Histone Modification on NKX2-5 Promoter in HLHS-Derived iPS cells 19 
To investigate further whether epigenetic modifications, such as histone H3 methylation and 20 
acetylation, could be involved in transcriptional regulation in HLHS-derived iPS cells during 21 
cardiac-lineage induction, ChIP assay was performed using CPCs, undifferentiated iPS cells, 22 
and differentiated iPS cells. Although there were no differences in methylation or acetylation 23 
modification at histone H3 in CPCs and undifferentiated iPS cells derived from HLHS and BV 24 
16 
 
patients, a marked decrease in dimethylated histone H3-lysine 4 (H3K4me2) and acetylated 1 
histone H3 (acH3) was found within the NKX2-5 promoter regions in differentiated 2 
HLHS-derived iPS cells compared with those from a BV patient. We also identified 3 
significantly increased trimethylated H3-lysine 27 (H3K27me3) in the differentiated 4 
HLHS-derived iPS cells (Figure 8). 5 
6 
17 
 
Discussion 1 
Congenital heart disease involves abnormalities in cardiac structure or function that arise before 2 
birth. Although a number of studies have uncovered that heterozygous mutations in cardiac 3 
regulatory genes caused congenital heart defects in humans, the identified genetic variants may 4 
not be directly correlated with biological insights that potentially contribute to disease 5 
development [20]. In lower vertebrates, the key regulatory mechanisms involved in early heart 6 
morphogenesis have been investigated extensively, but our understanding of the causal genes 7 
responsible for the development of such complex disease is still limited in humans [16]. Recent 8 
progress in stem cell biology has revealed a previously unappreciated aspect of cardiac 9 
morphogenesis that is genetically controlled by a series of lineage-restriction steps of common 10 
progenitor cells that arise from the primary cardiac crescent during development [21]. In this 11 
study, we employed an integrated approach by using patient-derived iPS cells to study the 12 
pathogenesis of HLHS in order to uncover the molecular fingerprints that may control 13 
progenitor cell fate during early cardiac development. 14 
Endogenous CPCs from adult mammalian heart were identified a decade ago [22,23]. 15 
Although human CPCs can also be used in cell culture to dissect the molecular mechanisms 16 
underlying congenital heart defects, investigation of inductive signals associated with early 17 
cardiogenesis by using postnatal cells, obtained after the onset of the disease of interest, may not 18 
be appropriate for the definitive identification of genes responsible for early developmental 19 
defects. In addition, it may not be possible to recapitulate the phenotypes by CPCs as in vitro 20 
sources because the pathogenesis of these complex diseases may require multiple cell types to 21 
initiate disease development. Reprogramming technology may facilitate disease investigation by 22 
assessing a wide variety of pluripotent stem cell differentiation pathways, including 23 
cardiomyogenic commitment, rather than by tracking the lineage-restricted progenitor cell fate. 24 
18 
 
In this regard, patient-specific iPS cells may represent a promising cell source to study disease 1 
mechanisms.  2 
There are several limitations in this study. The generation of patient-derived iPS cells 3 
remains technically demanding and clonal variation within patients or clones from other patients 4 
could be seen among studies; as such, their pathogenetic heterogeneity should not be ruled out. 5 
The lack of patients and control samples needs to be further emphasized and acknowledged 6 
could be a major limitation in this study. Whether the in vitro observations at 3 weeks after iPS 7 
cell differentiation could be used as a compatible model of embryonic heart development in 8 
humans remain unclear, so the obtained results may need to be interpreted with caution. Ethical 9 
concerns have limited the use of human CPCs isolated from healthy individuals due to the 10 
safety issues that must be considered during cardiac biopsy procedures. Our approach of using 11 
myocardial tissue specimens obtained during cardiac surgery in children was absolutely safe 12 
without any appearance of defects compared with the common skin biopsy procedures. With 13 
respect to a control, 201B7 iPS cells were used for comparative analysis in this study. We have 14 
also isolated disease-derived CPCs from a TAPVC patient in whom the pulmonary veins fail to 15 
enter the left atrium but supply the blood flow into the right atrium. Besides the malpositioned 16 
pulmonary vessels in this case, four-chamber morphogenesis and outflow tract developed 17 
normally in the presence of patent foramen ovale to support oxygenation. 18 
In this study, we found a series of transcriptional repression during the directed 19 
differentiation of HLHS-derived iPS cells, which are implicated in the development of HLHS 20 
(Figure 9A) and mutually controlled by a core-transcriptional regulatory network, including 21 
NKX2-5 and HAND [16]. These results are consistent with a previous mouse study 22 
demonstrating that the Nkx2-5-Hand1 transcriptional pathway plays an essential role in left 23 
ventricular formation during cardiogenesis [24]. Of particular note, potential NKX2-5 mutations 24 
19 
 
were found in patients with HLHS [25,26] and a frameshift mutation in HAND1 was reported 1 
[27]. The epigenetic signature of NKX2-5 transcripts in iPS cells during differentiation is 2 
unknown [28]. In general, undifferentiated stem cells show hypomethylation of specific gene 3 
promoters to allow their rapid activation during the processes of differentiation. Methylation at 4 
H3K4 is associated with transcriptional activation, whereas H3K27me3 represents a suppressive 5 
mark of condensed chromatin status. The results of ChIP assay suggest that reduced H3K4me2 6 
and increased H3K27me3 on the NKX2-5 promoter might be the alternative epigenetic 7 
mechanism to interpret the impaired transcriptional expression found in the differentiation 8 
processes of HLHS-derived iPS cells. 9 
The atrioventricular canal is located between atrial and ventricular chamber regions and is 10 
an essential source to complete endocardial cushion and valve development. Decreased inflow 11 
dynamics may lead to mitral stenosis/atresia as seen in HLHS. Although we did not observe 12 
significant changes in BOP1, which is a signaling control of secondary heart field development, 13 
combinatorial contributions by the NOTCH/HEY and TBX2 axes from both heart fields might 14 
specify this process in HLHS (Figure 9A) [18,29,30]. 15 
HLHS generally involves a predisposition to obstructed left ventricular outflow, which is 16 
commonly associated with aortic atresia [31]. The pathogenesis of HLHS may originate as a 17 
primary defect in valve development that leads to secondary LV hypoplasia (Figure 9A). 18 
NOTCH1 mutations have been identified in HLHS individuals and aortic valve anomalies 19 
[32,33]. Recent study related to NOTCH1 mutations in humans suggests a direct function of 20 
activated NOTCH and NOTCH ligand JAGGED complex in controlling myocardial growth 21 
through NKX2-5 activation [34,35]. The most prominent NOTCH effectors are basic 22 
helix-loop-helix transcription factors, HEY1/2. Endocardial NOTCH/HEY signal integration 23 
during endocardial to mesenchymal transition has been shown to be critical in the generation of 24 
20 
 
cardiac valve as a specialized structure [36]. Finally, HAND1 and HAND2 are preferentially 1 
expressed in primary and secondary heart fields to develop left and right chamber 2 
morphogenesis [37,38]. Although the role of Hand2 is generally essential in the secondary heart 3 
field [39], it was reported that the decreased expression of Hand2 in mice could influence 4 
formation of the LV and the aortic arch system [24], suggesting some implications in the 5 
phenotype of HLHS. 6 
 In this study, HLHS-derived iPS cells demonstrated lower capability of differentiating 7 
into cardiomyocytes (Figure 5B), which is consistent with a recent report showing that iPS cells 8 
generated from HLHS patients had impaired sarcomeric organization as well as altered calcium 9 
transient patterning and responses to -adrenergic antagonist during differentiation when 10 
compared with control iPS and human ES cells [40]. These observations indicate that 11 
HLHS-derived cells may have critical defects of transcriptional activation that are required for 12 
cardiac differentiation and organ morphogenesis of the heart. Among the genes analyzed in this 13 
study, NKX2-5, HAND1, and NOTCH1 were identified to be the essential transcripts to activate 14 
a subset of cardiac lineage-specific gene transcription. In contrast, the transcripts of GATA4 and 15 
TBX5 have been shown to be cooperatively involved in directing early cardiac transcriptional 16 
activation in vitro and in vivo; indeed, we only observed comparable expression of these genes 17 
between HLHS- and BV-derived cells during cardiac differentiation (data not shown) [41,42]. 18 
Novel insights have come from the gain- and loss-of-function experiments that demonstrated 19 
that these three transcription factors synergistically regulated SRE, TNNT2, and NPPA 20 
transcriptional activation (Figure 9B-D). Although the chromatin states of tissue-specific stem 21 
cells have been shown to be intermediate between pluripotent and differentiated cells [43], we 22 
found that HLHS-iPS-derived cardiomyocytes but not undifferentiated CPCs failed to acquire 23 
active histone marks at the NKX2-5 promoter region to achieve full cardiac-lineage induction 24 
21 
 
compared with BV-derived iPS cells (Figure 9E). These results suggest that epigenetic 1 
pre-patterning during development may also contribute to reduced cardiac-lineage specification 2 
and impaired heart morphogenesis in HLHS. 3 
In conclusion, patient-derived CPCs can be efficiently reprogrammed into disease-specific 4 
iPS cells for modeling congenital heart malformations. This integrated technology offers an 5 
unprecedented opportunity to reveal the genes differentially expressed between iPS cells with 6 
and without ventricular chamber defects and might enable correction of the gene variants for 7 
therapeutic purposes in HLHS. With knowledge of early cardiac development, the molecular 8 
regulatory networks that mediate myocardial growth and morphogenesis can be more 9 
informatively dissected by using patient-derived iPS cells. 10 
11 
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Figure Legends 1 
Figure 1. Reprogramming of disease-specific CPCs. 2 
(A) Schematic presentation of CPC isolation and iPS generation. (B) Retroviral transduction 3 
was verified by tagged-PCR and endogenous genes (C) are shown. (D) Retroviral silencing was 4 
confirmed during reprogramming after 3 months of infection. Trans- and endogenous-gene 5 
expressions are shown. 6 
 7 
Figure 2. Characterization of disease-specific iPS cells. 8 
Representative patient-specific iPS clones at passage 10 (A, iPS30: HLHS; B, iPS65: TAPVC, 9 
representing BV). Colonies were stained with transcription factors typically expressed in iPS 10 
cells. Bar, 200 m. (C and D) Bisulfite sequencing analysis of OCT4 and NANOG promoter 11 
regions during reprogramming is shown. Closed and open circles represent methylated and 12 
unmethylated CpG dinucleotides, respectively.  13 
 14 
Figure 3. Patient-specific CPCs were fully reprogrammed.  15 
(A) Representative images of alkaline phosphatase staining are shown for iPS cells generated 16 
from HLHS (iPS30) and TAPVC representing BV (iPS65) patients. Bar, 200 m. (B) 17 
Chromosomal abnormalities were not found in both iPS clones at 10 weeks by the G-banding 18 
method. (C) Heat map (right) and hierarchical cluster analysis (left) of global gene expression 19 
from patient-specific CPCs and iPS clones are shown. A commercially available 201B7 clone 20 
(Riken) was used as control human iPS cells.  21 
 22 
Figure 4. Patient-derived iPS cells differentiated into all three germ layer origins in vivo.  23 
Gross morphology and hematoxylin and eosin staining of patient-specific iPS cell-derived 24 
29 
 
teratomas are shown. Teratomas were found in the testes of NOD/SCID mice 10 to 12 weeks 1 
after transplantation. Histological sections of identified cells represent all three germ layers. Bar, 2 
50 m.  3 
 4 
Figure 5. HLHS-derived iPS cells could give rise to cardiomyocytes. 5 
(A) Both HLHS- and BV-derived iPS cells could generate cardiac troponin-T (TNNT2)-positive 6 
cardiomyocytes (green) 3 weeks after lineage induction. Nuclei were shown by DAPI (blue). 7 
Bar, 30 m. (B) Time course of TNNT2 expression in disease-specific iPS cells. Data were 8 
normalized using 2-microglobulin and human heart tissue for comparisons. *, p<0.05 vs. 9 
control and differentiated BV-derived iPS cells at 3 weeks. †, p<0.05 vs. before cardiac lineage 10 
induction (0 weeks) in each group. 11 
 12 
Figure 6. HLHS-iPS cell-derived cardiomyocytes showed decreased cardiac transcripts.  13 
mRNA expressions in control 201B7 iPS cells and one BV- and two HLHS-derived iPS cell 14 
lines during cardiac lineage induction at respective time points were determined by quantitative 15 
RT-PCR. All data were obtained from more than five independent experiments with three 16 
different clonal derivatives and normalized using 2-microglobulin and human heart tissue for 17 
comparisons. *, p<0.05 vs. differentiated 201B7 and BV-derived iPS cells at corresponding time 18 
points. †, p<0.05 vs. 201B7 at corresponding time points. 19 
 20 
Figure 7. Synergistic restoration of target promoters by NKX2-5, HAND1, and NOTCH in 21 
HLHS-derived CPCs and iPS cells. 22 
Transcriptional activation of SRE promoter luciferase construct by combinatorial transfection of 23 
NKX2-5, HAND1, and NOTCH1 in HLHS- and BV-derived CPCs (A) or iPS cells (B). 24 
30 
 
Co-transfection of TNNT2 luciferase reporter with NKX2-5, HAND1, and NOTCH1 in CPCs 1 
(C) or iPS cells (D) is shown. NPPA luciferase construct was co-transfected with NKX2-5, 2 
HAND1, and NOTCH1 alone or in combination into CPCs (E) or iPS cells (F). (G-I) 3 
BV-derived CPCs were transfected with either control or shRNAs specific to inhibit NKX2-5, 4 
HAND1, and NOTCH1 expression. Results were normalized using an internal control (SEAP or 5 
hRluc) and obtained from more than triplicate sets of experiments. *, p<0.05 vs. the same 6 
HLHS sample without transfection of the gene of interest. †, p<0.05 vs. BV sample transfected 7 
with control vector alone. ‡, p<0.05 vs. both HLHS samples with the same treatment. §, p<0.01 8 
vs. BV sample transfected with control vector alone.      9 
 10 
Figure 8. HLHS-iPS cell-derived cardiomyocytes showed suppressed H3K4 methylation 11 
and H3 acetylation, but increased H3K27 methylation. 12 
Undifferentiated CPCs (A) and iPS cells (B) and differentiated (cardiac-lineage induction for 3 13 
weeks) iPS cells (C) were analyzed by ChIP assay. N.D., not detected; *, p<0.05 vs. 14 
differentiated BV-derived iPS cells. Data are expressed as the percentage of input DNA. 15 
 16 
Figure 9. Orchestrated gene regulatory network in the development of HLHS. 17 
(A) Core transcriptional factors expressed in cardiac progenitor cells serve as targets in response 18 
to inductive signals to initiate cardiogenesis. NKX2-5 is predominantly expressed in the primary 19 
heart field and controls progenitor cell proliferation. Genes regulate atrioventricular (AV) canal 20 
and valve development. Reduced expression may contribute to mitral- and aortic-valve 21 
stenosis/atresia often seen in HLHS. NOCTH modulates left heart outflow tract development 22 
and the resultant obstruction may cause secondary ventricle hypoplasia. HAND1/2 specify left 23 
and right ventricular chamber morphogenesis, and the absence of these genes may lead to a 24 
31 
 
hypoplastic ventricle. (B-D) Schematic diagrams of SRE, TNNT2, and NPPA transcriptional 1 
activation. HLHS-derived CPCs and iPS cells showed significantly reduced luciferase activities 2 
compared with BV-derived cells. Co-transfection analysis of reporter constructs with NKX2-5, 3 
HAND1, and NOTCH1, proposed core transcriptional factors, could synergistically restore the 4 
transcriptional activation in these reporters equivalent to the levels in BV-derived cells. (E) 5 
Major chromatin features in differentiated HLHS- and BV-derived iPS cells are shown. Upon 6 
cardiomyocyte differentiation, HLHS-derived iPS cells failed to enrich the active histone marks 7 
such as H3K4me2 and acH3, whereas repressive histone marks such as H3K27me3 increased, 8 
resulting in compact chromatin that lost enhancer marks and gained repressor marks on the 9 
NKX2-5 promoter.  10 
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